Drug Trial Radar · NCT01820585
Efficacy and Safety of Eslicarbazepine Acetate as Therapy in Subjects With Fibromyalgia
Last checked: Nov 20, 2026Latest source record: Jul 19, 2013 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
528
Actual
Start
Apr 2009
Primary completion
Sep 2010
Study completion Sep 2010
Sponsor
- Lead sponsor
- Bial - Portela C S.A.Industry
- Sponsor type
- Industry
- First posted
- Mar 29, 2013
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This was a double-blind, randomised, placebo-controlled, parallel-group, multicentre, multinational, Phase II study in 528 subjects with pain due to Fibromyalgia syndrome(FMS). Subjects were randomised in a 1:1:1:1 ratio to receive placebo, Eslicarbazepine acetate (ESL) 400 mg once daily (QD), ESL 800 mg QD or ESL 1200 mg QD. The study was carried out as follows.
Conditions
- Fibromyalgia
Interventions
PlaceboDrug
Tablets
ESL 400 mgDrug
tablets
ESL 800 mgDrug
tablets
ESL 1200 mgDrug
tablets
Primary outcomes
What the sponsor says the trial is designed to measure.
- Absolute Change From Baseline to Endpoint in Mean PainTime frame: Baseline and 13 Weeks
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.